Privatlivspræferencer
Inderes bruger cookies for at give en bedre brugeroplevelse og en personlig service. Ved at give samtykke til brugen af cookies kan vi udvikle en endnu bedre service og vil kunne levere indhold, der er interessant for dig.
  • Forum
  • Aktiemarkeder
    • MarkederRealtidskurser, indekser og markedsudvikling
    • BørskalenderKommende resultater, noteringer og virksomhedsbegivenheder
    • UdbyttekalenderKommende og tidligere udbytter
  • Selskaber
    • SelskaberGennemse og filtrer den fulde liste over børsnoterede selskaber
    • OpdagInspiration til din næste investering
    • BørsnoteringerNye noteringer og kommende børsintroduktioner
    • Invitationer til generalforsamlingerDatoer for generalforsamlinger og aktionærinformation
  • Aktieanalyse
    • ResearchEkspertaktieanalyse og anbefalinger
    • ArtiklerNyheder, indsigter og markedskommentarer
    • inderesTVVideocenter for aktieanalyse, forskning og ekspertkommentarer
    • TransskriptionerFuldstændige udskrifter af resultatopkald og investormøder
    • AktieoversigtSammenlign nøgletal og udvikling på tværs af flere aktier
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.

Circio Holding

Mindre end 1K følgere

CRNA

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Investorernes syn

Circio Holding is a pharmaceutical company. The company's specialist expertise is found in targeted immunotherapy used in the treatment of cancer patients. The company's operations consist of research and development and the medicines are sold under separate brands. Several partnerships in the market have been entered into to strengthen cooperation in the development of new immunotherapy. The company was founded in 2010 and is headquartered in Lysaker.

Læs mere
Markedsværdi
-
Aktieomsætning
-
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Alle
Selskabsmeddelelser
ViserAlle indholdstyper

Selskabsmeddelelse24.09.2026, 13.47

Circio Holding ASA: Issuance of restricted stock units (RSUs) to the board members

Circio Holding
Selskabsmeddelelse23.09.2026, 13.08

Circio Holding ASA: Cancellation of Subsequent Offering

Circio Holding
Selskabsmeddelelse22.09.2026, 10.33

Circio Holding ASA: Registration of share capital increase following private placement of approximately NOK 200 million

Circio Holding

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Selskabsmeddelelse15.09.2026, 08.50

Circio Holding ASA: Mandatory notification of trade (share lending in connection with private placement)

Circio Holding
Selskabsmeddelelse15.09.2026, 08.35

Circio Holding ASA: Ex. right to participate in potential subsequent offering today

Circio Holding
Selskabsmeddelelse15.09.2026, 08.35

Circio Holding ASA: Ex. right to participate in potential subsequent offering today

Circio Holding
Selskabsmeddelelse15.09.2026, 08.30

Circio Holding ASA: Key information relating to potential subsequent offering

Circio Holding
Selskabsmeddelelse15.09.2026, 08.24

Circio announces that it has completed a capital raise of approx. NOK 200 million towards its in vivo CAR-T program

Circio Holding
Selskabsmeddelelse31.08.2026, 20.05

Circio presents strong R&D, financing and business development progress in first half year report

Circio Holding
Selskabsmeddelelse26.08.2026, 07.00

CRNA: Circio and Full Circles Therapeutics jointly announce in vivo cell therapy research

Circio Holding
Pressemeddelelse26.08.2026, 07.00

Circio and Full Circles Therapeutics jointly announce in vivo cell therapy research

Circio Holding
Selskabsmeddelelse25.08.2026, 18.35

Circio Holding ASA: Minutes from the extraordinary general meeting 25 August 2026

Circio Holding
Selskabsmeddelelse25.08.2026, 07.00

Circio invites to live webcast on 1 September 2026 at 10:00 am CEST

Circio Holding
Selskabsmeddelelse06.08.2026, 07.00

Circio selected to deliver oral presentation at the prestigious ESGCT annual meeting

Circio Holding
Selskabsmeddelelse04.08.2026, 11.06

Circio nominates RNA and gene therapy US industry veteran Dr. Dinah Sah to its Board of Directors

Circio Holding
Selskabsmeddelelse04.08.2026, 11.05

Circio Holding ASA – Notice of extraordinary general meeting on 25 August 2026

Circio Holding
Selskabsmeddelelse16.07.2026, 08.58

CRNA: Circio and Avenue Biosciences jointly announce research collaboration to enhance protein secretion for gene therapy

Circio Holding
Pressemeddelelse16.07.2026, 08.58

Circio and Avenue Biosciences jointly announce research collaboration to enhance protein secretion for gene therapy

Circio Holding
Selskabsmeddelelse24.06.2026, 07.00

Circio and Tcelltech jointly announce CAR-T cell therapy research collaboration

Circio Holding
Selskabsmeddelelse22.06.2026, 14.05

Circio Holding ASA – Share capital increase registered

Circio Holding